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Inhaled corticosteroids (ICS) have a very favourable ratio
of topical vs. systemic activity. To assess the systemic
availability and/or potency of dierent types of ICS,
measurements are used that reflect the function of the
hypothalamic–pituitary–adrenal (HPA) axis (1). The most
sensitive measurements of the function of the HPA axis
include measurement of cortisol levels in multiple blood
samples with frequent sampling, particularly overnight or
for 12–24 h, measurement of cortisol production through
steroid measurements in urine collected overnight or for
24 h, and stimulation tests with adrenocorticotropic
hormone (ACTH) (2,3).
Using these tests, it has been shown that ICS may, in a
dose-dependent manner, reduce cortisol secretion into
serum [reflected in a reduced area under the concentra-
tion-time curve {AUC} and overnight or 24-h urinary-free
cortisol (UFC) excretion] and total cortisol metabolite
output. Stimulation tests using supraphysiological dosages
of 250 or 500 mg 1?73m72 ACTH usually do not reveal
changes in the function of the HPA axis. In contrast, the
response to a low (physiological) dose of ACTH (0?5mg
1?73m72) was dampened in *30% patients on treatment
with beclomethasone dipropionate (BDP) or budesonide
(BUD) (daily dose*500 mg m72) (4). Thus, ICS appear to
downregulate the production and secretion of cortisol,
reflecting their systemic activity. This, however, has no
clinical significance in the vast majority of adult patients
treated with these drugs at recommended doses.
There are two routes by which ICS can enter the systemic
circulation. The majority of the inhaled fraction which is
delivered into the lung easily enters the pulmonary
circulation and is systemically available before inactivation
in the liver takes place. The fraction deposited in the
oropharynx is swallowed and its systemic availability is
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following oral absorption and first-pass metabolism is very
low with currently used ICS [BDP *20%, BUD *11%,
and fluticasone propionate (FP) *1%], most of the ICS
systemically available is derived from absorption via the
airways. As a consequence, one would expect that
the greater the pulmonary deposition of a particular ICS,
the higher the serum levels of that ICS and metabolites, and
thus the greater the suppression of cortisol secretion would
be. Dierences in these eects among ICS are likely to be
explained by, for example, dierences in lipophilicity,
receptor binding kinetics, and/or plasma elimination time.
Recent data, however, suggest that this relationship
between serum levels of ICS and changes in serum cortisol
levels is not that straightforward. Chlorofluorocarbon
(CFC) containing pressurized aerosolized medications have
been reformulated, using hydrofluoroalkanes (HFA) as
propellants (5). The reformulated BDP (HFA-134a-BDP)
represents a change from the current CFC suspension
formulations to that of a solution formulation. This change
has resulted in an HFA-134a-BDP aerosol with a lower
median mass aerodynamic diameter (MMAD) in compar-
ison with CFC-BDP, being*1?1mm instead of*3?5–4 mm
in CFC-BDP (6). The respirable mass of HFA-134a-BDP is
*52% compared with*35% for the CFC-BDP (7). In line
with these in vitro characteristics, the lung deposition of
HFA-134a-BDP is much higher (i.e. *54% of delivered
dose) compared with *9% with CFC-BDP (8).
As a consequence, serum concentrations of total
beclomethasone [i.e. unchanged BDP, beclomethasone-17-
monopropionate (17-BMP), beclomethasone-21-monopro-
pionate (21-BMP), and beclomethasone-free base (BOH),
referred to as total-BOH (9)] following HFA-134a-BDP
inhalation are increased compared with a similar dose of
CFC-BDP. HFA-134a-BDP in a dose of 400mg resulted in
a maximal serum total BOH concentration (Cmax) of
1191 pg ml71 vs. 410 pg ml71 for 400 mg CFC-BDP, and
a serum AUC of total-BOH of 4962 pg hml71 vs.
2092 pg hml71 for CFC-BDP (10). There was also a
significant dierence in serum Tmax of total-BOH; 0?8 h
after HFA-134a-BDP vs. 2 h for CFC-BDP.
Thus, the enhanced lung deposition of HFA-134a-BDP
results in more than doubling of serum total BOH
concentration. There is no linear relationship between# 2000 HARCOURT PUBLISHERS LTD
628 P. N. R. DEKHUIJZEN AND J. W. HONOURserum total BOH concentrations and 24-h UFC concentra-
tions; doubling of the AUC from 2000 pg hml71 to
4000 pg hml71 results in only about a 10% reduction in
the 24-h UFC (9). Even such a reduction of cortisol
production, however, was not observed after HFA-134a-
BDP. Two weeks of inhalation of HFA-134a-BDP 800 mg
daily reduced UFC by (median) *38% vs. *48% after
inhalation of CFC-BDP 800 mg daily (P=NS) (11).
Morning serum cortisol levels and the response to a
conventional (high) dose of ACTH were also not dierent
among HFA-134a-BDP and CFC-BDP-treated patients.
Before discussing potential explanations, we briefly
discuss the regulation of adequate systemic cortisol levels
by the HPA axis.
Features of the HPA axis
In a 24-h period serum cortisol levels change most during
the night with the highest levels between 06:00 and 10:00
hours and the lowest levels at midnight [Fig. 1(a)]. The
timing and frequency of sampling influences the extent to
which this is accurately portrayed. In contrast to the
representation of the diurnal rhythm as often published,
blood sampling at 10-min intervals shows that three or four
peaks of increasing amplitude and 90-min frequency may
be defined. The actual peak concentrations may be higher
than recorded, conversely nadir concentrations may beFIG. 1. Course of plasma cortisol levels during a 24-h
period. Each dot represents a separate blood sample. (a)
A healthy subject without any medication; (b) an
asthmatic subject on ICS.lower. The actual pattern is a sawtooth curve and follows
serum ACTH concentrations (12,13). Blood samples need
to be taken even more frequently (2-min intervals) to define
ACTH pulsatility because of the short half-life of this
peptide hormone.
In many studies, frequent blood samples have been taken
and the mean or integrated cortisol concentration was
calculated. Typically mean serum cortisol levels are 140–
400 nmol l71 in normal subjects but 50–300 nmol l71 in
ICS-treated patients. Instead of a normal pattern of several
peaks of cortisol during the night a patient taking ICS
shows a delay in the time of onset of pulsatility and a
reduction in the number of peaks up to mid-morning
[Fig. 1(b)].
ACTH regulates cortisol secretion in three, partly
interrelated ways (i) The circadian rhythm is controlled by
a biological clock in the midbrain, and is mediated by
variations in corticotrophin releasing factor (CRF) from
the hypothalamus. This hormone regulates the synthesis
and release of ACTH by the basophilic cells of the anterior
pituitary. ACTH is released in around 30–50 secretory
bursts per 24 h. The magnitude (amplitude) of the bursts,
but not the frequency, varies during the day, with a 3?8-fold
higher amplitude at 08:00 hours compared to midnight (12).
This pattern is closely followed by serum cortisol levels. (ii)
A negative feedback system regulates that CRF, ACTH and
cortisol secretion are reduced when serum corticosteroid
levels are too high, and, conversely, increased when serum
corticosteroid levels are too low. (iii) Stress accounts for a
rapid increase in CRF, ACTH and cortisol secretion,
irrespective of the time of day or state of the feedback
system.
The interaction between ACTH and steroidogenesis has
a fast and a slow component. The acute eect, occurring
within minutes, comprises the conversion of cholesterol to
d5-pregnenolone, the initial and rate-limiting step in
cortisol biosynthesis. The chronic eects, requiring hours
or days, involve increased synthesis of most of the enzymes
required for the steroidogenesis. ACTH-mediated secretion
accounts for *70% of total cortisol production. The
remaining part is controlled by neurotransmitters, neuro-
peptides, inflammatory and other cytokines, growth factors
and lipid mediators (3).
Cortisol in the circulation is largely bound to cortisol
binding globulin (CBG), and to a lesser extent, to albumin.
At cortisol concentrations around 400 nmol l71, only 3% of
the cortisol is free in plasma. Most methods for the
quantitative determination of cortisol in plasma measure
the total concentrations. Free cortisol in plasma is filtered
at the kidney glomerulus and is not reabsorbed by the
tubules. Cortisol is normally excreted in the urine at a rate
of less than 200 nmol day71. Normal concentrations of free
cortisol in urine are often less than 100 nmol l71, especially
in children. At these low levels (either due to normal
variation or suppression by steroids) the immunoassays can
be imprecise.
Hepatic metabolism of cortisol is largely by reduction,
after which the steroid metabolites are conjugated before
excretion in the urine. The sum of the excretion rates of
individual cortisol metabolites in the urine for 24 h is an
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production rate of cortisol (14). The daily production rate
of cortisol is 6–9mgm72 body surface area when measured
using stable isotope dilution techniques. In blood, cortisol
has a half-life of 25–35min.
Basal adrenal activity in patients is often assessed by a
single morning plasma concentration. Due to the circadian
rhythm in cortisol secretion as described above, extended
period measurements such as repeated plasma cortisol
levels over 24 h or during the night, free cortisol excretion in
the urine, and urine excretion rates of cortisol metabolites
are more sensitive but rather impractical measures. One-
time measurement of plasma cortisol concentration should
only be used as a screening test in individual patients
because of quite large inter-individual variations in
circadian cortisol rhythms (15). When glucocorticoids are
administered in the evening, the nocturnal pattern may be
shifted into the day. Such variations may invalidate one-
time measurements in clinical trials. The pattern of results
from repeated sampling of blood or urine over time,
however, is very reproducible in individual subjects and
influences from inter-individual variations in diurnal
rhythms are reduced. Blood samples need to be taken at a
minimum of 15-min intervals to be able to define the pulses
of cortisol. The use of integrated cortisol results is not a
very sensitive test of adrenal function. More of the samples
throughout the 24-h period have results below 300 nmol l71
than above that concentration and these results dilute out
the integrated level.
A plasma cortisol concentration higher than 200 nmol
l71 at 08:00 hours makes adrenal insuciency unlikely, and
further testing may not be needed. If plasma cortisol is
below 200 nmol l71 and fails to respond to a pharmaco-
logical dose of 250mg ACTH, then a prolonged ACTH test
should be performed (16). The potential risk of anaphylac-
tic reactions to ACTH testing is very low.
Nocturnal and 24-h UFC excretion in the urine benefit
from being non-invasive measures but are inconvenient for
the patient to perform. The dierence, if any, between the
sensitivity of the two measures is small (2). Some reports
have found correction for creatinine to be useful, but
rigorous comparisons with measures of absolute UFC
concentrations have not been reported (17,18). However,
the sensitivity of measures of UFC excretion appears to
depend on quite a small dose window. When cortisol
secretion is suppressed, an initial reduction in UFC
excretion occurs, but a state is reached in which cortisol
binding proteins in the plasma are not saturated and the
free cortisol and hence the free cortisol output in the urine
will be low. At such concentrations there is also an increase
in the imprecision of detection of cortisol in the urine.
Together with a decrease in the analytical specificity of
cortisol measurement this may explain why dose related
eects may not be detected (19,20). These problems can be
avoided by measuring the excretion of cortisol metabolites
in 24-h urine. This measure combines non-invasiveness with
a high sensitivity in the assessment of dose-related
suppressive eects of topical glucocorticoids (21).
In clinical trials, adrenal stimulation is most frequently
performed by ACTH. An increase in the plasma cortisolconcentration after i.v. or i.m. administration of ACTH
(ACTH-1-24, Synacthen) 250 mg to above 500 nmol l71, or
an increment in the plasma cortisol from 0 to 30min of
220 nmol l71 are usually regarded as acceptable responses
to adrenal stimulation. It is important to be aware that
standard stimulation tests of the HPA axis do not reflect
cortisol responses to minor stress. The adrenal gland is
stimulated for probably a day after such a pharmacological
dose of the peptide hormone. When lower doses of
Synacthen are used (typically 500 ng) the test can be
reproducible (22) although care must be taken in the
dilution and delivery of the hormone to obtain repeatable
data. Doses of ACTH 500 times lower than the conven-
tional test dose of 250mg are more sensitive in detection of
suppressed responses in adults on ICS (see above) (4,22,23).
Although childhood cases of clinical glucocorticoid
excess (24,25) and subnormal HPA stimulation results in
patients on high doses of ICS (26) have been reported, there
is no evidence that ICS in recommended doses have caused
clinically significant HPA-axis insuciency. Adrenal sti-
mulation tests may therefore only be needed in patients on
concomittant long term systemic glucocorticoids or on high
doses of ICS. Whether there may be a place for adrenal
testing in patients on concomittant insuated and inhaled
preparations remains to be evaluated.
Impact of ICS on the HPA axis
Now, the question is how the HPA axis reacts to ICS that
enter the systemic circulation. It is well established that
exogenous glucocorticoids suppress cortisol production by
feedback mechanisms that act simultaneously on the
hypothalamus and the pituitary in a similar way to
endogenous glucocorticoids (3). There is also a possible
direct eect on the adrenal cortex itself. After i.v. infusion
of a dose of a steroid there is a triphasic feedback on ACTH
secretion (27). The fast reaction occurs within minutes and
continues for about 20–30min. Increasing the administered
dose only increases the suppressive eect on ACTH
secretion but does not aect the duration of this reaction.
The intermediate reaction occurs after 30–40min and
continues for 18–36 h. This reaction depends on the dose
of the steroid administered. Slow feedback, occurring after
days, involves reduction of the pituitary ACTH content by
reducing the levels of mRNA encoding for the ACTH
precursor molecules.
Coming back to the initial issue, being the cause of a
dierence in reaction of the HPA axis to HFA-134a-BDP
and CFC-BDP, several potential mechanisms can be
formulated, which either can be rejected based upon the
current literature, or have to be explored.
ARE THERE DIFFERENCES IN THE ICS
METABOLIC PRODUCTS ENTERING THE
SYSTEMIC CIRCULATION?
BDP is metabolized in humans primarily to 17-BMP, 21-
BMP and beclomethasone-free base (BOH). Studies with
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binding anity resides with 17-BMP. Pharmacokinetic
studies of inhaled HFA-134a-BDP have confirmed that
BDP is converted to 17-BMP within minutes. 17-BMP
circulates in the serum, for up to 12 h at higher levels than
unchanged BDP or other metabolites. Further metabolism
to BOH occurs primarily in the liver. One might expect
dierent metabolic profiles between HFA-134a-BDP and
CFC-BDP, i.e. HFA-134a-BDP gives more 17-BMP in the
systemic circulation (after absorption from the lungs), while
CFC-BDP gives mainly BOH in the systemic circulation
after oral absorption and first pass metabolism in the liver
(28). The question then remains whether HPA axis reacts in
a dierent way to these dierent metabolite profiles.
DO DIFFERENCES IN CONCENTRATION-
TIME RELATIONSHIPS AFFECT THE HPA
AXIS IN A DIFFERENT WAY?
The question arises whether the feedback loop works like a
thermostat in that once glucocorticoid activity reaches a
certain level secretion is stopped and not started again until
the critical level is attained or is it more dependent on the
direction and rate of change in activity. It may be
hypothesized that a shorter ‘rise time’ (i.e. Tmax) gives less
input to the HPA axis to change its output of CRF and
ACTH.
ARE THERE DIFFERENCES IN RECEPTOR
AFFINITIES AMONG THE ICS
METABOLITES
Perhaps because of the dierent lipophilicity associated
with each metabolite, the receptors for the systemic eect of
BDP have the opposite binding anities to that observed
for clinical ecacy, i.e. BOH4417-BMP. If this were the
case, then HFA-134a-BDP, because it deposits more 17-
BMP in the lungs and produces less BOH, would indeed be
expected to have an improved therapeutic index over a
product that deposits less 17-BMP in the lungs and
produces more BOH.
It is clear that only incomplete answers can be given on
the questions stated above. The data, however, show that
our straightforward concept of increased systemic eect on
the HPA axis as a result of increased pulmonary deposition
and subsequent increased serum levels of metabolites of
BDP needs to be reconsidered.
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